The cost of pulmonary thromboembolism treatment

Bugra Coskuner M., ÖZTUNA F., BÜLBÜL Y., Ozsu S.

TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, cilt.68, sa.3, ss.293-304, 2020 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 68 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5578/tt.70104
  • Dergi Adı: TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, CAB Abstracts, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.293-304
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Introduction: Primary aim of this study is to determine the financial burden of Vitamin K Antagonists (VKA), low molecular weight heparins (LMWH) and new oral anticoagulants (NOAC) which are used in the treatment of the pulmonary thromboembolism (PTE). Secondary aim is to show long term complications of the treatment options.